Mantle Cell Lymphoma (MCL) Treatments

Find Mantle Cell Lymphoma (MCL) Treatments

Brand Name

Calquence

Generic Name

Acalabrutinib

View Brand Information

FDA approval date: October 31, 2017

Classification: Kinase Inhibitor

Form: Tablet, Capsule

What is Calquence (Acalabrutinib)?

CALQUENCE is a kinase inhibitor indicated: In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma

Who is this study for: Adult patients with diffuse large B-cell lymphoma

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Biological, Drug

Study Drugs: DA-EPOCH, Rituximab, CHOP, Acalabrutinib

Study Phase: Phase 2

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate.

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or Azer-cel) in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Who is this study for: Adult patients with B Cell CD19-Positive Acute Lymphoblastic Leukemia

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Drug, Biological

Study Drugs: CD19-Positive CAR-T Cells, Cyclophosphamide, Fludarabine

Study Phase: Phase 1

Summary: This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

View All Clinical Trials

Related Latest Advances

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.

Journal: Fortune journal of health sciences

Published: August 13, 2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 07, 2026

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

Journal: The Medical letter on drugs and therapeutics

Published: July 14, 2026

View All Latest Advances